ThomasFountaineMD

Oncology • Rochester, NY

Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology, Sarcoma

Medical Director, Clinical Development Tmunity Therapeutics, Inc

Join to view full profile

Dr. Fountaine is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fountaine's full profile

Already have an account?

Office
601 Elmwood Ave
Rochester, NY 14642
Phone+1 585-275-5863

Fax+1 585-273-5761

Education & Training

Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 2014 - 2017
University of RochesterChief Residency, Pediatrics, 2013 - 2014
University of RochesterResidency, Pediatrics, 2010 - 2013
Pennsylvania State University College of MedicineClass of 2010

Certifications & Licensure

NY State Medical License 2012 - 2025
MD State Medical License 2015 - 2016
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Publications & Presentations

PubMed

887 citations
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Terry J. Fry, Nirali N. Shah, Rimas J. Orentas, Maryalice Stetler-Stevenson, Constance M. Yuan
Nature Medicine. 2018-01-01
300 citations
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
Elad Jacoby, Sang M. Nguyen, Thomas J. Fountaine, Kathryn M. Welp, Berkley E. Gryder
Nature Communications. 2016-07-27
177 citations
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22.
Haiying Qin, Sneha Ramakrishna, Sang M. Nguyen, Thomas J. Fountaine, Maryalice Stetler-Stevenson
Molecular Therapy Oncolytics. 2018-12-21

Abstracts/Posters

Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide
Thomas J Fountaine, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

A Specific Mesenchymal Stem and Progenitor Cell (MSPC) Subpopulation with a Multi-Potent Gene Signature Is Transcriptionally Altered in the Setting of Myelodysplastic ...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Dr. Thomas Fountaine of the University of Rochester Medical Center Wilmot Cancer Institute Joins the Assistance Fund’s Medical Advisory BoardNovember 12th, 2018